Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial
Background As per the National Medical Products Administration (NMPA) requirements, the quality and efficacy of generic drugs must be consistent with those of the innovator drug. We aimed to evaluate the bioequivalence and safety of generic metformin hydrochloride sustained-release (MH-SR) tablets (...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2022.2125574 |
| _version_ | 1811208982529835008 |
|---|---|
| author | Ming-Li Sun Chen Liu Hai-Hong Bai Ya-Li Wei Wei Zhang Hui-Juan Liu Yin-Juan Li Long Liu Yu Wang Yuan-Xv Tong Qian Gao Qian-Ying Liu Xinghe Wang |
| author_facet | Ming-Li Sun Chen Liu Hai-Hong Bai Ya-Li Wei Wei Zhang Hui-Juan Liu Yin-Juan Li Long Liu Yu Wang Yuan-Xv Tong Qian Gao Qian-Ying Liu Xinghe Wang |
| author_sort | Ming-Li Sun |
| collection | DOAJ |
| description | Background As per the National Medical Products Administration (NMPA) requirements, the quality and efficacy of generic drugs must be consistent with those of the innovator drug. We aimed to evaluate the bioequivalence and safety of generic metformin hydrochloride sustained-release (MH-SR) tablets (Boke®) developed by Beijing Wanhui Double-crane Pharmaceutical Co. Ltd., China and the innovator product metformin hydrochloride extended-release tablets (Glucophage®-XR) manufactured by Bristol-Myers Squibb Company, New York, NY, in healthy Chinese volunteers.Materials and methods We performed a bioequivalence and safety assessment of MH-SR (500 mg/tablet) and Glucophage®-XR (500 mg/tablet) tablets in a randomized, open-label, two-period, two-sequence crossover, single-dose oral study in 48 healthy Chinese adult participants under fasting conditions (Chinese Clinical Trial Registration No. CTR20171306). The washout period was seven days. Bioequivalence (80.00–125.00%) was assessed using adjusted geometric mean ratios (GMRs) and two-sided 90% confidence intervals (CIs) of the area under the curve (AUC) and maximum concentration (Cmax) for each component.Results The 90% CIs of the test/reference preparation for key pharmacokinetic parameters were 97.36–108.30% for AUC0→t, 97.26–108.09% for AUC0→∞ and 96.76–111.37% for Cmax. No severe adverse events (AEs) were observed. However, 38 adverse drug reactions (ADRs) occurred, including metabolic or nutritional conditions (n = 8), infections (n = 2), gastrointestinal conditions (n = 10) and abnormal inspection (n = 18). No significant difference was observed between MH-SR (23 ADRs, 10 participants) and Glucophage®-XR (15 ADRs, 12 participants) (p = .500). Bioequivalence was concluded since the 90% CIs of the main pharmacokinetic parameters were within the equivalence interval (80.00–125.00%).Conclusions MH-SR (500 mg/tablet) and Glucophage®-XR (500 mg/tablet) were found to be bioequivalent and safe under fasting conditions in healthy Chinese participants. Thus, the market demand for MH-SR tablets (500 mg/tablet) can be met using the generic alternative.KEY MESSAGESGeneric MH-SR tablets (500 mg, Beijing Wanhui Double-crane Pharmaceutical Co. Ltd., Beijing, China) and innovator MH-SR tablets (Glucophage®-XR, 500 mg, Bristol-Myers Squibb Company, New York, NY, USA) were bioequivalent and safe in healthy Chinese volunteers under single-dose administration and fasting conditions.The main goal of this study is to support an increase in the supply of MH-SR tablets in China by proving the efficacy and safety of a generic alternative.Although no sugar was administered in the BE trial of the MH-SR tablets under fasting conditions, no hypoglycaemic event occurred. The method used in this study is expected to serve as a reference for BE studies of different MH-SR formulations. |
| first_indexed | 2024-04-12T04:32:22Z |
| format | Article |
| id | doaj.art-611c93be1ba54bcf8cba3db30933ef51 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-04-12T04:32:22Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-611c93be1ba54bcf8cba3db30933ef512022-12-22T03:47:54ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602022-12-015412617262610.1080/07853890.2022.2125574Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trialMing-Li Sun0Chen Liu1Hai-Hong Bai2Ya-Li Wei3Wei Zhang4Hui-Juan Liu5Yin-Juan Li6Long Liu7Yu Wang8Yuan-Xv Tong9Qian Gao10Qian-Ying Liu11Xinghe Wang12Phase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaDivision of Medicine, China Resources Double-Crane Pharmaceutical Co. Ltd., Beijing, P. R. ChinaResearch and Development Department, China Resources Double-Crane Pharmaceutical Co. Ltd., Beijing, P. R. ChinaPhase I Clinical Trial Centre, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, P. R. ChinaBackground As per the National Medical Products Administration (NMPA) requirements, the quality and efficacy of generic drugs must be consistent with those of the innovator drug. We aimed to evaluate the bioequivalence and safety of generic metformin hydrochloride sustained-release (MH-SR) tablets (Boke®) developed by Beijing Wanhui Double-crane Pharmaceutical Co. Ltd., China and the innovator product metformin hydrochloride extended-release tablets (Glucophage®-XR) manufactured by Bristol-Myers Squibb Company, New York, NY, in healthy Chinese volunteers.Materials and methods We performed a bioequivalence and safety assessment of MH-SR (500 mg/tablet) and Glucophage®-XR (500 mg/tablet) tablets in a randomized, open-label, two-period, two-sequence crossover, single-dose oral study in 48 healthy Chinese adult participants under fasting conditions (Chinese Clinical Trial Registration No. CTR20171306). The washout period was seven days. Bioequivalence (80.00–125.00%) was assessed using adjusted geometric mean ratios (GMRs) and two-sided 90% confidence intervals (CIs) of the area under the curve (AUC) and maximum concentration (Cmax) for each component.Results The 90% CIs of the test/reference preparation for key pharmacokinetic parameters were 97.36–108.30% for AUC0→t, 97.26–108.09% for AUC0→∞ and 96.76–111.37% for Cmax. No severe adverse events (AEs) were observed. However, 38 adverse drug reactions (ADRs) occurred, including metabolic or nutritional conditions (n = 8), infections (n = 2), gastrointestinal conditions (n = 10) and abnormal inspection (n = 18). No significant difference was observed between MH-SR (23 ADRs, 10 participants) and Glucophage®-XR (15 ADRs, 12 participants) (p = .500). Bioequivalence was concluded since the 90% CIs of the main pharmacokinetic parameters were within the equivalence interval (80.00–125.00%).Conclusions MH-SR (500 mg/tablet) and Glucophage®-XR (500 mg/tablet) were found to be bioequivalent and safe under fasting conditions in healthy Chinese participants. Thus, the market demand for MH-SR tablets (500 mg/tablet) can be met using the generic alternative.KEY MESSAGESGeneric MH-SR tablets (500 mg, Beijing Wanhui Double-crane Pharmaceutical Co. Ltd., Beijing, China) and innovator MH-SR tablets (Glucophage®-XR, 500 mg, Bristol-Myers Squibb Company, New York, NY, USA) were bioequivalent and safe in healthy Chinese volunteers under single-dose administration and fasting conditions.The main goal of this study is to support an increase in the supply of MH-SR tablets in China by proving the efficacy and safety of a generic alternative.Although no sugar was administered in the BE trial of the MH-SR tablets under fasting conditions, no hypoglycaemic event occurred. The method used in this study is expected to serve as a reference for BE studies of different MH-SR formulations.https://www.tandfonline.com/doi/10.1080/07853890.2022.2125574Bioequivalencecrossover trialsmetformin hydrochloridepharmacokineticsfasting conditions |
| spellingShingle | Ming-Li Sun Chen Liu Hai-Hong Bai Ya-Li Wei Wei Zhang Hui-Juan Liu Yin-Juan Li Long Liu Yu Wang Yuan-Xv Tong Qian Gao Qian-Ying Liu Xinghe Wang Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial Annals of Medicine Bioequivalence crossover trials metformin hydrochloride pharmacokinetics fasting conditions |
| title | Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial |
| title_full | Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial |
| title_fullStr | Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial |
| title_full_unstemmed | Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial |
| title_short | Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial |
| title_sort | bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained release tablets boke r and glucophage r xr in healthy chinese volunteers a randomized phase i clinical trial |
| topic | Bioequivalence crossover trials metformin hydrochloride pharmacokinetics fasting conditions |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2022.2125574 |
| work_keys_str_mv | AT minglisun bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT chenliu bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT haihongbai bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT yaliwei bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT weizhang bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT huijuanliu bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT yinjuanli bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT longliu bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT yuwang bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT yuanxvtong bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT qiangao bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT qianyingliu bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial AT xinghewang bioequivalenceandsafetyevaluationoftwopreparationsofmetforminhydrochloridesustainedreleasetabletsbokeandglucophagexrinhealthychinesevolunteersarandomizedphaseiclinicaltrial |